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Background




Boronic acid compounds are the focus of increasing interest as therapeutic agents due to their ability 
to inhibit enzyme activity, among other characteristics.   Many peptide boronic acid compounds have been 
investigated as enzyme inhibitors with implications in pathologies as varied as Alzheimer’s disease, cervical 
cancer, blood clotting disorders, hepatitis C, etc. (1).  In 2003 the drug Velcade® (bortezomib), figure 1, 
was approved by the FDA as a second-line treatment for multiple myeloma, it acts via inhibition of the 26S 
proteasome in mammalian cells (2).  As shown in scheme 1, the role of the boronic acid moiety in this 
inhibition is to interact with the hydroxyl of the N-terminal threonine of the β-subunit of the proteasome (3).
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While the pharmacologic properties of these 
compounds appears to be impressive, there are obstacles 
to their formulation into suitable dosage forms.  One 
obstacle is their apparent low solubility.  Workers have
observed solubility values for boronic acid containing compounds well below that of the respective non-
boronic acid containing analog (4).  It was also noted that solubility could be increased by adding 
monosaccharides to the aqueous solutions (4).  Further, the formulators of Velcade® observed an increase 
in the solubility of the drug when it was lyophilized in the presence of mannitol (5). They attributed this to 
the formation of boronic acid esters, shown in green, and the simultaneous avoidance of forming the less 
soluble trimeric boroxine species shown in orange (Figure 2). A further explanation of this increased 
solubility is a pKa lowering effect that polyols impart to boronic acids (Figure 3). The mechanism by 
which polyols help solubilize boronic acid containing compounds is not completely understood and 
deserves further study.
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A large change in the UV spectra of 4-MBBA is observed at 
235nm, this was utilized in pKa determination by UV 
spectrophotometric titrations (Figure 7). 
Figure 10 demonstrates the correlation between polyol size and pKa lowering effect.   As 
the number of hydroxyls on the polyol increases, the effect on  4-MBBA increases.  The 
greatest effect comes from mannitol and xylitol, as the pKa lowering effect plateaus at 
around pKa 6.2, almost a full 3 units below the original pKa of ~9.2.
•The solid state of boronic acids and boronate esters will be studied, 
with a particular emphasis on how to exploit the formulation of boronic 
acid containing drugs with polyols in order to maximize the binding 
phenomena.
•The solubility and dissolution of boronates will be explored in greater 
detail to further elucidate the mechanism of boronate ester and boroxine 
dissolution to yield free boronic acids.
Scheme 1




























































































































Structure of Velcade® (bortezomib)
Future Work



































































The titration of 4-MBBA is shown (Figure 8). The curve 
is fit to a modified Henderson-Hasselbach equation.
Potentiometric titrations were also performed using a Mettler-Toledo 
DL-53 autotitrator and the pKa values were calculated as described 
by Albert and Serjeant (6). Figure 9 shows the type of data 
























Figure 4 demonstrates the 
large effect mannitol has on the 
solubility of 4-MBBA.  Highlighted 
in green is the effect at physiologic 
pH, a 10-fold increase in solubility.  
Figures 5 and 6 illustrate the direct 
effect on the pKa as determined 
from the solubility pH profile, as 
described by equation 1.  Through 
figure 6 one can see that the ratio of 
mannitol to boronic acid has an 
effect on solubility through pKa. 
Isothermal Titration 
Calorimetry
















































































Figure 10 Figure 11 Figure 12
Figure 11 illustrates the utility of the potentiometric technique, described above, in studying the 
effect of glucose and fructose on the apparent pKa of 4-MBBA.  The UV spectrophotometric 
technique could not be used due to spectral interference, most likely the carbonyl group.  The 
mannitol experiment confirms that both the UV spectrophotometric and potentiometric titration 
techniques yield the same results, when accounting for the different concentrations used in the 
experiments.  Fructose decreased the apparent pKa of 4-MBBA slightly greater than did mannitol, 
and much greater than did glucose.
Figure 12 applies the potentiometric technique to the study of IBA an alkyl boronic 
acid.  It is critical to demonstrate that this phenomenon occurs with alkyl boronic 
acids, because most boronic acid containing drugs are alkyl, not aryl boronic acids.  
First, this series of experiments shows that a similar drop in pKa occurs, roughly 3 
units or greater for the highest binding polyols, when alkyl or aryl boronic acids form 
boronate esters.  Second, the rank order of the polyols’ effect is maintained. 












Structure 1 Structure 2
The objective of the following research is to determine the effect of various polyols on the physical and 
chemical properties of two model boronic acids; 4-methoxybenzeneboronic acid (4-MBBA) shown in 
structure 1, and isobutylboronic acid (IBA) illustrated in structure 2.  The research will quantify the ability of
the polyols, first, to form boronate esters with the model 
compounds.  Second, to determine the effect that this 
formation has on the pKa and solubility of the boronate 
compound.  This information should provide crucial 
insights to the formulation chemist when developing 
boronic acid containing pharmaceuticals.


















































































Q is the total heat
ΔH is the enthalpy of binding
K is the binding constant
n is the number of binding sites
V is the volume of the reaction cell
[L] is the ligand concentration





Figure from User’s Manual Revision 12705, 
Calorimetry Sciences Corp., Lindon, UT
30mM Mannitol Titrated into 
1mM 4-MBBA at pH 11.6
30mM Mannitol Titrated into 
1mM 4-MBBA at pH 11.6
Isothermal titration calorimetry 
or ITC, is a calorimetric 
analytical techniques which 
measures the heat evolved or 
absorbed upon titrating a 
solution of ligand into a solution 
of receptor.  The instrumental 
setup is shown in figure 13.  As 
the mole ratio increases during 
the titration and there is less free 
receptor, the total heat per 
injection decreases, as shown in 
figure 14.  This profile is 
described, for a molecule with a 
single set of receptors,  by 
equation 2.  Thus, the data may 
be fit, as in figure 15, and one 
may solve for the variables: N, 
K, ΔH, and ΔS
The ITC data confirms the rank order of polyol effects observed during 
pKa lowering studies.  Further, the binding constants observed are on the 
same order as those predicted from the pKa lowering studies.
•pKa determination by UV spectroscopic and potentiometric titrations have identified that some high binding 
polyols decrease the pKa of a boronate by over three units. The high binding polyols include some common 
pharmaceutical excipients.
•This effect occurs in both aryl and alkyl boronic acids, and is maintained regardless of the starting pKa of the 
unbound boronic acid. Further, the rank order of polyol effect is maintained from alkyl to aryl boronic acids.
•Isothermal titration calorimetry confirms that a boronic acid-polyol binding correlates with this pKa lowering 
effect.
•Solubility studies show that pKa lowering of boronic acids by polyols has a large effect on the solubility of 
















Interaction of various polyols with 4-methoxybenzene boronic 
acid as the receptor in ITC experiments
